Bladder cancer
Open
Phase 1/2
This study is looking at durvalumab in combination with the S-488210/S-488211 vaccine to treat non muscle invasive bladder cancer.
Recruitment start: 25 March 2022
Recruitment end: 1 January 2027
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Mark Linch
University College London (UCL)
CRUK & UCL Cancer Trials Centre
Shionogi & Co Ltd
AstraZeneca
Last reviewed: 31 Oct 2025
CRUK internal database number: 18501
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
